Compare Alcon AG (ALC) vs Twist Bioscience Corp (TWST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Twist Bioscience Corp — how do they compare? Alcon AG trades at $66.95 (market cap $32.69B), while Twist Bioscience Corp trades at $89.51 (market cap $5.67B). The key difference: Alcon AG is far larger — about 5.8× Twist Bioscience Corp's market cap, and Alcon AG pays a 0.54% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| ALC | TWST | |
|---|---|---|
Market Cap | $32.69B | $5.67B |
Sector | Health | Health |
52-Week High | $92.22 | $102.88 |
52-Week Low | $62.02 | $24.16 |
Enterprise Value | $36.28B | $5.59B |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Twist Bioscience (TWST) trades at $91.03, down 8.27% in the past day, amid mixed earnings performance. The stock shows a bullish technical trend with strong moving average signals, though RSI levels indicate overbought conditions. Revenue growth remains robust, rising to $377 million in 2025, but profitability challenges persist with a net income margin of -19.85%. Recent news highlights AI-driven drug discovery collaborations and insider selling activity.
The outlook is cautiously optimistic given analyst consensus favoring buys (76.93%) and a price target near current levels. Key risks include sustained cash burn, competitive pressures in synthetic biology, and execution on path to profitability. Upside hinges on revenue acceleration and margin improvement from new product launches and AI partnerships.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Twist Bioscience Corp
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →
